Meridian Medical Launches Line of Ophthalmic Lasers in the US

Following a series of FDA approvals, Switzerland-based Meridian Medical is launching its line of ophthalmic lasers in the US.

On January 25, Meridian received FDA approval for the MR Q family of lasers. The lasers include:

• MR Q, a fully integrated ND:YAG laser combined with a precision optics LED slit lamp with a magnification range from 6 × up to 40 × selectable in 5 fixed steps
• MR Q SLT, an Nd:YAG laser combined with an selective laser trabeculoplasty (SLT) photo-regenerator
• MR Q supine, an Nd:YAG laser designed to treat patients in supine position, featuring ergonomic 0–210° tiltable Haag-Streit binoculars to improve the surgeons’ comfort and visual quality

The FDA approval of the MR Q line comes after Meridian received FDA approval in September 2023 for the Merilas line of lasers, including the Merilas 532 alpha green laser photocoagulator, Merilas 532 shortpulse single spot laser, Merilas 577 shortpulse yellow laser photocoagulator, and Merilas 810 shortpulse diode laser therapy for glaucoma and retina treatment.

"In the 87 years of Meridian Medical AG, we've achieved many milestones. Entering the US market will be considered among them,” Marco Obbens, Meridian Medical chief operating officer, said in a statement to Eyewire+. “With the addition of the MR Q family of products joining the Merilas line, we offer a complete portfolio to fill the unmet ophthalmic laser needs and growing demand for reliable, high-performance, precision laser instruments that we clearly see exists. We are excited as we look forward into 2024 and beyond, and we'd like to thank the FDA for granting us this opportunity."

For more information on Meridian Medical and its technology, visit meridian.ch.